StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $0.13 | $0.12 | -9.26% | 2.7M |
| 05-08 | $0.11 | $0.12 | +8.00% | 1.9M |
| 05-11 | $0.11 | $0.11 | +0.00% | 2.0M |
| 05-12 | $0.11 | $0.09 | -19.74% | 12.5M |
| 05-13 | $0.08 | $0.08 | +10.94% | 3.2M |
Press releases, AI summaries, and links to free transcript sources. Audio webcasts live on the issuer's IR site.
Press releases served direct from sec.gov. Stonvex doesn't host transcript bodies — these require the publisher's terms.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $3.19K | $2.77K | $2.02K | $1.02K |
Operating Income | $-19.57M | $-14.90M | $-11.76M | $-5.61M |
Net Income | $-43.10M | $-37.01M | $-12.97M | $-5.71M |
EPS (Diluted) | $-1153.83 | $-1605.17 | $-9.22 | $-8.12 |
Total Assets | $16.52M | $11.80M | $32.69M | $31.22M |
Total Liabilities | $12.56M | $20.66M | $20.70M | $15.46M |
Cash & Equivalents | $3.20M | $163.04K | $323.68K | $476.42K |
Free Cash Flow OCF − CapEx | $-25.70M | Not available | Not available | Not available |
Shares Outstanding | 411.50K | 50.92K | 3.18M | 1.21M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.